Anne Sibille

Durvalumab as third-line or later treatment for advanced non-small-cell lung cancer (ATLANTIC): an open-label, single-arm, phase 2 study

Marina Chiara Garassino, Byoung Chul Cho, Joo-Hang Kim et al. · The Lancet Oncology · 2018 · 568 citations · Full text

Medicine, Immunology, Pathology +5

Treatment Characteristics and Real-World Progression-Free Survival in Patients With Unresectable Stage III NSCLC Who Received Durvalumab After Chemoradiotherapy: Findings From the PACIFIC-R Study

Nicolas Girard, Jair Bar, Pilar Garrido et al. · Journal of Thoracic Oncology · 2022 · 203 citations · Full text

Asthma and COPD Are Not Risk Factors for ICU Stay and Death in Case of SARS-CoV2 Infection

Doriane Calmès, Sophie Graff, Nathalie Maes et al. · The Journal of Allergy and Clinical Immunology In Practice · 2020 · 89 citations · Full text

Veliparib in Combination with Carboplatin and Etoposide in Patients with Treatment-Naïve Extensive-Stage Small Cell Lung Cancer: A Phase 2 Randomized Study

Lauren A. Byers, Dmitry Bentsion, Steven Gans et al. · Clinical Cancer Research · 2021 · 72 citations · Full text

Radiomics and Delta-Radiomics Signatures to Predict Response and Survival in Patients with Non-Small-Cell Lung Cancer Treated with Immune Checkpoint Inhibitors

François Cousin, Thomas Louis, Sophie Dheur et al. · Cancers · 2023 · 43 citations · Full text